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Abstract 
Background: Postprandial hyperlipidemia impairs endothelial function and participates in the 
development of atherosclerosis. We investigated the postprandial effects of a dipeptidyl peptidase 
IV inhibitor, alogliptin, on endothelial dysfunction and the lipid profile. 
Methods: A randomized cross-over trial design in 10 healthy volunteers (8 males and 2 females, 
35 ± 10 years) was performed. The postprandial effects before and after a 1-week treatment of 25 
mg/day alogliptin on endothelial function were assessed with brachial artery flow-mediated 
dilation (FMD) and changing levels of lipids, apolipoprotein B48 (apoB-48), glucose, glucagon, 
insulin, and glucagon-like peptide-1 (GLP-1) during fasting and at 2, 4, 6, and 8 h after a 
standard meal loading test. 
Results: Alogliptin treatment significantly suppressed the postprandial elevation in serum 
triglyceride (incremental area under the curve [AUC]; 279 ± 31 vs. 182 ± 32 mg h/dl, p = 0.01), 
apoB-48 (incremental AUC; 15.4 ± 1.7 vs. 11.7 ± 1.1 μg h/ml, p = 0.04), and remnant lipoprotein 
cholesterol (RLP-C) (incremental AUC: 29.3 ± 3.2 vs. 17.6 ± 3.3 mg h/dl, p = 0.01). GLP-1 
secretion was significantly increased after alogliptin treatment. Postprandial endothelial 
dysfunction (maximum decrease in %FMD, from −4.2 ± 0.5% to −2.6 ± 0.4%, p = 0.03) was 
significantly associated with the maximum change in apoB-48 (r = −0.46, p = 0.03) and RLP-C (r 
= −0.45, p = 0.04). 
Conclusion: Alogliptin significantly improved postprandial endothelial dysfunction and 
postprandial lipemia, suggesting that alogliptin may be a promising anti-atherogenic agent. 
 
Key words: Dipeptidyl peptidase IV inhibitor; postprandial lipid; triglyceride-rich lipoprotein, 
endothelial dysfunction; alogliptin 
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1. Introduction 
Large prospective studies have shown that non-fasting postprandial triglyceride (TG) 
concentrations predict cardiovascular risk better than fasting TG concentrations and that this 
relationship is independent of traditional coronary risk factors [1, 2]. TG-rich lipoproteins, which 
consist of chylomicrons assembled by TG, dietary cholesterol, and apolipoprotein B-48 
(apoB-48), are highly atherogenic and contribute to the development of coronary heart disease. 
Thus, the increased risk of cardiovascular events associated with non-fasting TG concentrations 
may reflect atherogenic properties of TG-rich lipoproteins generated during the postprandial 
period [3]. Studies have shown that postprandial lipemia contributes to the production of 
proinflammatory cytokines and oxidative stress, resulting in endothelial dysfunction even in 
healthy normolipidemic people [4, 5]. Furthermore, other studies demonstrated that postprandial 
hyperlipemia caused by oral fat intake impairs endothelial dysfunction as detected with 
flow-mediated dilatation (FMD) of the brachial artery in healthy volunteers. This endothelial 
dysfunction is associated with postprandial TG-rich lipoproteins [6, 7]. Therefore, identification 
of novel therapeutic approaches that would beneficially affect postprandial concentrations of 
lipids is of great interest. 
Alogliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4) and has been 
shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes, 
presumably by inhibiting the inactivation of glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP), thereby improving islet function [8-10]. 
Recent clinical studies have reported that DPP-4 inhibitors such as vildagliptin and sitagliptin 
improve postprandial atherogenic TG-rich lipoprotein levels in patients with type 2 diabetes [11, 
12]. However, the effects of other DPP-4 inhibitors on postprandial lipemia-induced endothelial 
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dysfunction have not been fully evaluated. 
The aim of this study was to investigate the effects of alogliptin on postprandial triglyceride 
(TG)-rich lipoprotein and postprandial lipemia-induced endothelial dysfunction. 
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2. Methods 
2.1. Participants 
Ten volunteers, including eight men and two women, were recruited. The study consisted of 
two 1-week cross-over treatment periods with 25 mg/day alogliptin and placebo in random order, 
including a 1-week washout period between the two phases. All participants underwent medical 
check-ups. None of the 10 volunteers had hypertension, impaired glucose tolerance, dyslipidemia, 
or cerebrovascular or cardiovascular disease, but three volunteers were current smokers. Family 
histories were obtained from medical interviews. Impaired glucose tolerance was defined as 2-h 
glucose level of 140–199 mg/dl after the meal loading test [13], and dyslipidemia was defined as 
one or more of the following criteria at the fasting state: (1) serum triglyceride ≥150 mg/dL, (2) 
HDL-cholesterol <40 mg/dL, and (3) LDL-cholesterol ≥140 mg/dL [14]. Lipid profiles and 
endothelial function, which was assessed with brachial artery FMD during fasting and at 2, 4, 6, 
and 8 h after an oral cookie loading test, were determined following each phase of treatment. 
Participants were instructed to take one tablet after their morning meal. This study was approved 
by the Ethics Committee of Okayama University Graduate School of Medicine, Dentistry, and 
Pharmaceutical Sciences, and written informed consent was obtained from all volunteers before 
beginning the protocol. 
2.2. Study protocol 
After overnight fasting for at least 8 h, a cookie test was performed. The cookie consisted of 75 
g carbohydrate (flour starch and maltose), 28.5 g fat (butter), and 8 g protein for a total of 592 
kcal per a carton (SARAYA Corp., Osaka, Japan) [15]. Participants were instructed to ingest the 
cookie with water within 20 min. Time measurement was started when half the cookie had been 
ingested. Venous blood samples were drawn, and endothelium-dependent vascular function, as 
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assessed with FMD of the brachial artery, was determined during the fasting state before cookie 
ingestion and at 2, 4, 6, and 8 h after the cookie load. Endothelium-independent dilation, as 
assessed with nitroglycerin-mediated dilation (NMD), was also measured during fasting before 
cookie ingestion and 8 h after the cookie load. For the 8 h after eating the cookie, the participants 
were instructed not to eat anything else. Measurements of FMD and NMD were performed by the 
same technician, who was blinded to the study design and medication status.  
2.3. Measurement of biochemical parameters 
The following parameters during fasting before cookie ingestion were measured: serum total 
cholesterol (Total-C), TG, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein 
cholesterol (HDL-C), remnant lipoprotein cholesterol (RLP-C), apoB-48, adiponectin, soluble 
vascular cell adhesion molecule 1 (VCAM-1), and plasma glucose levels. HbA1c levels were 
measured using high-performance liquid chromatography. Concentrations of fasting plasma 
insulin were measured using a chemiluminescent enzyme immunoassay. Lipid profiles and other 
markers were measured at SRL Co., Ltd., Tokyo, Japan. Homeostasis model assessment of 
insulin resistance (HOMA-IR) was calculated as [fasting plasma glucose (mg/dl) × fasting 
plasma insulin (μIU/ml)/405]. Serum Total-C, TG, LDL-C, HDL-C, RLP-C, apoB-48, plasma 
glucose, and soluble VCAM-1 were measured at 2, 4, 6, and 8 h after the cookie load. To 
compare the postprandial changes in these parameters before and after treatment for 4 weeks, the 
area under the curve (AUC) was calculated using the trapezoidal method. 
2.4. FMD measurement 
Endothelium-dependent and -independent dilation was assessed as a parameter of 
vasodilation according to the guidelines for ultrasound assessment of FMD of the brachial artery 
[16]. Using a 10-MHz linear-array transducer probe (Unex Company Ltd., Nagoya, Japan), 
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longitudinal images of the brachial artery at baseline were recorded with a stereotactic arm, and 
measurements of artery diameter were made after supine rest for ≥5 min. The diameter of the 
artery was measured from clear anterior (media-adventitia) and posterior (intima-media) 
interfaces, which were manually determined. Then, suprasystolic compression (50 mmHg higher 
than systolic blood pressure) was performed at the right forearm for 5 min, and measurements of 
artery diameter were made continuously from 30 s before to ≥2 min after cuff release. After ≥10 
min of rest from FMD measurement, artery diameter at baseline and for 5 min after 
administration of 0.3 mg sublingual nitroglycerin was also measured. Maximum vasodilation was 
then evaluated from the change in artery diameter after release of occlusion (%FMD) and after 
administration of nitroglycerin (%NMD). 
2.5. Statistical analysis 
Sample size was determined based on the estimated FMD reported in another recent study 
[7]. We assumed that the mean improvement in postprandial %FMD was 2.7% and the standard 
deviation (SD) was 2.0%. To use a two-sided test for differences, a minimal sample size of 10 
participants was required in each group to detect statistical differences in %FMD with a power of 
80% and an α-type error of 5% in statistical analysis. Results and data in the figures are expressed 
as the mean ± standard error (SE). Categorical variables were compared using the 2 test or 
Fisher's exact test. Differences in lipid profile and endothelial function between the two groups 
were compared using the Wilcoxon signed-ranks test. Pearson correlation coefficients were used 
to assess the relationships between maximum reduction in postprandial %FMD and lipid profiles. 
Values of p < 0.05 were considered significant. 
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3. Results 
3.1. Characteristics of participants 
The mean age and body mass index of these volunteers were 35 ± 10 years and 23.9 ± 4.1 
kg/m2, respectively. Participants maintained their weight throughout the study. Table 1 shows the 
lipid/lipoprotein profile and the glycemic parameters of the participants following each 1-week 
phase of either control or treatment with 25 mg/day alogliptin. During fasting, 1-week treatment 
with alogliptin did not affect the lipid/lipoprotein profile or the levels of adiponectin and soluble 
VCAM-1. Alogliptin significantly increased GLP-1 levels with no significant impact on fasting 
blood glucose or HOMA-IR (insulin resistance). No significant differences were observed in 
systolic and diastolic blood pressure following alogliptin treatment. 
3.2. Postprandial lipid and glucose homeostasis 
The levels of lipid/lipoprotein, parameters of glucose homeostasis, and soluble VCAM-1 in 
the postprandial state are shown in Fig. 1 and Supplementary Table 1 (see supplementary data). 
The serial changes in parameters following each 1-week phase of either control or treatment with 
alogliptin are shown in Fig. 1. In the control group, the postprandial levels of serum TG, RLP-C, 
apoB-48, and GLP-1 increased and peaked at 2 or 4 h and then returned to baseline at 8 h. The 
levels of glucose, total-C, LDL-C, HDL-C, and soluble VCAM-1 did not change significantly 
during the postprandial state. Therefore, the nominal maximum changes and the incremental 
AUCs of TG, RLP-C, ApoB-48, glucose, and GLP-1 were calculated. The total AUCs of total-C, 
LDL-C, HDL-C, glucagon, and soluble VCAM-1 were also calculated for comparison.  
The maximum changes in postprandial TG, RLP-C, ApoB-48, and GLP-1 were significantly 
smaller in the alogliptin group compared with the control group (Table 2). The incremental AUCs 
of serum TG, RLP-C, and apoB-48 were significantly lower in the alogliptin group than in the 
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control group (incremental AUC of TG: 279 ± 31 mg vs. 182 ± 32 mg h/dl, p = 0.01; RLP-C: 
29.3 ± 3.2 vs. 17.6 ± 3.3 mg h/dl, p = 0.01; apoB-48: 15.4 ± 1.7 vs. 11.7 ± 1.1 μg h/ml, p = 0.04). 
No differences in the total AUCs of total-C, LDL-C, or HDL-C were observed between the 
alogliptin group and the control groups (total AUC of total-C: 1452 ± 252 vs. 1489 ± 248 mg h/dl, 
p = 0.68, LDL-C: 814 ± 228 vs. 819 ± 218 mg h/dl, p = 0.72, HDL-C: 514 ± 71 vs. 532 ± 79 mg 
h/dl, p = 0.10). 
Regarding parameters of glucose homeostasis, there were no significant differences in the 
incremental AUCs of glucose or insulin between the alogliptin and control groups (incremental 
AUC of glucose: 78 ± 15 vs. 77 ± 8 mg h/dl, p = 0.58, insulin: 48.3 ± 10.9 vs. 49.4 ± 14.7, p = 
0.96), although the incremental AUC of GLP-1 was increased in the alogliptin group (33.8 ± 5.2 
vs. 18.2 ± 4.4 pmol h/l, p = 0.02). The total AUC of glucagon was decreased significantly after 
alogliptin treatment (451.9 ± 21.9 vs. 515.6 ± 30.4 pg h/ml, p = 0.02). No significant difference 
was observed in the level of soluble VCAM-1 between the alogliptin and control groups (4931 ± 
1528 vs. 4935 ± 1411 ng h /ml, p = 0.79).  
3.3. Postprandial endothelial function 
Comparison of postprandial endothelial function, which was assessed as %FMD, between the 
control and alogliptin groups is shown in Fig. 2. In the control group, postprandial %FMD 
decreased significantly, reached the lowest level at 4 h (from 11.8 ± 0.6 to 7.7 ± 0.3%, fasting vs. 
4 h, p < 0.01), and recovered at 8 h (from 11.8 ± 0.6 to 12.3 ± 0.5%, fasting vs. 8 h, p = 0.15). 
The maximum decrease in postprandial %FMD was significantly improved after alogliptin 
treatment compared to the control group (−2.6% vs. −4.2%, p = 0.03). In the analysis of all data 
using the control and alogliptin groups, linear regression analysis revealed that the maximum 
reduction in postprandial %FMD was significantly associated with maximum increases in 
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postprandial TG, RLP-C, and apoB-48 concentrations (TG: r = −0.45, p = 0.04; RLP-C: r = −0.45, 
p = 0.04; apoB-48: r = −0.47, p = 0.03), and tended to be correlated with the maximum change in 
GLP-1 (r = 0.39, p = 0.08). However, the maximum reduction in postprandial %FMD was not 
associated with the maximum change in postprandial LDL-C, HDL-C, glucose, or soluble 
VCAM-1.
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4. Discussion 
This study demonstrated that alogliptin treatment significantly reduced postprandial levels of 
intestinally derived apo-B48–containing lipoproteins, which were induced by a conventional oral 
cookie loading test (28.5 g fat per person), and that alogliptin improved postprandial 
lipemia-induced endothelial dysfunction. Considering the significant association between the 
beneficial change in endothelial dysfunction and the decrease in TG-rich lipoproteins, 
cardiovascular risk, especially associated with postprandial lipemia, may be reduced with 
long-term treatment with alogliptin.  
Our study with the oral cookie test showed that a greater increase in TG-rich lipoprotein, but 
not glucose, was correlated with postprandial FMD impairment in healthy volunteers. This study 
did not include people with impaired glucose tolerance and dyslipidemia. Our finding suggests 
that the impairment in endothelial dysfunction induced by postprandial lipemia is more common 
than that induced by postprandial hyperglycemia in the general population. As reported in other 
studies, postprandial hyperglycemia induces endothelial dysfunction, especially in patients with 
diabetes mellitus or glucose intolerance. In these patients, an increase in glucose is also 
associated with postprandial endothelial dysfunction [17]. Furthermore, patients with diabetes 
mellitus often show dyslipidemia including postprandial hyperlipemia. Therefore, our results 
suggest that alogliptin therapy possibly improves glucose metabolism as well as postprandial 
hyperlipemia and postprandial endothelial dysfunction in patients with diabetes mellitus.  
Previous studies showed that DPP-4 inhibitors such as vildagliptin and sitagliptin decrease 
postprandial TG, RLP-C, and apoB-48 levels after a fat-loading test in patients with type 2 
diabetes [11, 12]; however, our study is the first to show that alogliptin reduces the postprandial 
increase in triglyceride-rich lipoproteins in non-obese nondiabetic subjects. 
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This study was not designed to examine the molecular mechanisms underlying the effect of 
alogliptin on postprandial hyperlipemia, but several mechanisms are possible. A study showed 
that GLP-1 influences intestinal TG absorption [18], potentially by inhibiting gastric lipase [19]. 
Animal studies have shown that DPP-4 inhibition or GLP-1 receptor agonists significantly reduce 
intestinal secretion of TG, cholesterol, and apoB-48, suggesting that GLP-1 may directly regulate 
lipoprotein assembly or the secretion in enterocytes [20]. As shown in our previous study, 
administration of ezetimibe, an inhibitor of cholesterol absorption, improves postprandial 
lipemia-induced endothelial dysfunction, mainly due to suppression of postprandial TG-rich 
lipoproteins [7]. In our current study, the maximum decrease in FMD was significantly associated 
with the maximum change in TG, RLP-C, and apoB-48, but not glucose. Although further studies 
are needed to determine the extent to which decreased TG absorption and increased chylomicron 
clearance contribute to the alogliptin-induced reduction in postprandial lipid response, these 
findings support our concept that alogliptin markedly decreases the levels of postprandial 
TG-rich lipoproteins, resulting in prevention of postprandial lipemia-induced endothelial 
dysfunction. 
Regarding another proposed mechanism of improvement in postprandial endothelial 
dysfunction, an increase in active GLP-1 after alogliptin administration may have direct favorable 
effects on vascular function. An experimental study reported that sitagliptin improves endothelial 
function and reduces proinflammatory cytokines and atherosclerosis in apoE-deficient mice [21]. 
Another experimental study showed that a GLP-1 analog reduces oxidative stress in endothelial 
cells [22]. A clinical study showed that vildagliptin improves endothelium-dependent 
vasodilatation as determined by plethysmography in patients with type 2 diabetes in a fasting 
state [23]. Postprandial inflammation and oxidative stress, which are well known to affect the 
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metabolism of nitric oxide and the release of vasoconstrictive mediators, result in endothelial 
dysfunction [5, 24]. In our study, we did not examine the effect of alogliptin on postprandial 
oxidative stress. We evaluated the levels of soluble VCAM-1 as a marker of vascular 
inflammation, but no significant difference was observed. Therefore, we cannot conclude whether 
the administration of alogliptin improves postprandial inflammation and oxidative stress. A 
previous study compared the effects of α-glucosidase inhibitors on postprandial glucose/lipid 
metabolism and endothelial dysfunction in patients with diabetes and showed that miglitol was 
better than voglibose regarding a greater reduction in triglyceride and a greater induction of 
GLP-1 [25]. In addition, another study showed that a single dose of exenatide improves 
postprandial endothelial dysfunction in individuals with impaired glucose tolerance and 
recent-onset type 2 diabetes. These clinical studies indicate that GLP-1 has direct favorable 
effects on postprandial endothelial dysfunction [26]. In our current study, no difference was 
observed between the alogliptin and control groups in glucose levels at 2 h, which was probably 
due to our use of healthy volunteers. Even though we did not compare alogliptin and other 
glycemic control agents in this study, a greater spike in GLP-1 after the fat-loading test and/or a 
greater secretion of GLP-1 after each meal for 1 week in the alogliptin group may have partly 
contributed to the protective effect on postprandial endothelial dysfunction.  
A clinical report showed that sitagliptin treatment for 3 months increases adiponectin levels 
in patients with diabetes mellitus [27]. This report also suggests that improvement of endothelial 
function by sitagliptin therapy is associated with the change in adiponectin. An experimental 
study also showed that sitagliptin significantly increases circulating levels of adiponectin in 
OLETF rats [28]. Adiponectin has vasoprotective effects via regulation of endothelial nitric oxide 
synthase in vascular endothelial cells. Even though our study failed to show a significant increase 
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in adiponectin levels after 1 week of treatment with alogliptin—probably owing to short-term 
administration—the long-term effect of alogliptin therapy on adiponectin levels needs to be 
elucidated. 
There is mixed evidence for the benefits of improved glycemic control on cardiovascular 
events and mortality in patients with diabetes mellitus. The 10 years of primary follow-up from 
the landmark UK Prospective Diabetes Study (UKPDS) [29] and three recent outcome studies 
(the Action to Control Cardiovascular Risk in Diabetes [ACCORD] [30], Action in Diabetes and 
Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation [ADVANCE] 
[31], and Veterans Affairs Diabetes Trial [VADT] [32]) all failed to demonstrate that intensive 
glycemic control reduces cardiovascular events and mortality. In contrast, recent studies showed 
that a DPP-4 inhibitor may reduce cardiovascular events in patients with diabetes [33]. 
Experimental studies also showed the favorable action of DPP-4 on vascular cells via a 
GLP-1-independent mechanism [34]. These data indicate that DPP-4 may have potential for 
preventing cardiovascular events beyond glycemic control; however, another group reported that 
vildagliptin has no protective effects on cardiac function in a rat model of post-myocardial 
infarction heart failure [35]. Thus, the cardiovascular benefits of DPP-4 inhibitors beyond 
glycemic control should be clarified in a future study.  
4.1. Study limitations 
There are several important limitations of our study. First, this was an open-label study, and 
the number of participants enrolled in our study was small. Therefore, a degree of selection bias 
may have occurred. Second, no widely used method for assessing postprandial hyperlipemia has 
been established, and so various fat-loading tests, such as oral fat meal, fat cream intake, and 
intravenous fat load, have been used in previous studies. We used the cookie test, which provided 
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sufficient information about glucose intolerance and postprandial hyperlipemia [13]. Although 
the cookie provided a fixed amount of fat (28.5 g) per person, the amount of fat given per body 
surface area was not the same in this study. Therefore, the contribution of each person’s fat 
metabolism cannot be ruled out as an influential factor. A meal loading test using 30 g fat/m2 
body surface area showed a greater increase in TG and RLP compared with that using a fixed 
amount of fat (28.5 g) per person, even in healthy volunteers [7]. The effect of alogliptin on 
postprandial lipemia after the meal loading test with 30 g fat/m2 body surface area would also be 
informative, especially in patients with diabetes or dyslipidemia. 
In conclusion, we demonstrated that inhibition of DPP-4 with alogliptin was effective for 
reducing postprandial elevation of TG-rich lipoproteins and the accompanying induction of 
postprandial endothelial dysfunction. Alogliptin may be a useful drug for reducing future 
cardiovascular disease by ameliorating endothelial dysfunction in the postprandial state, even in 
low-risk patients. 
 
Conflicts of interest 
None. 
 
Acknowledgment 
We thank Koaru Akazawa, Masayo Ohmori, and Miyuki Fujiwara for their excellent technical 
support. 
 
Authors' contributions 
YN, TM, JO, KN, conceived the study, and participated in its design and coordination and helped 
16 
 
to draft the manuscript. 
YN, TM, YO carried out examinations 
NT, KK, HM, KK, HI were involved in drafting the manuscript or revising it critically 
All authors read and approved the final manuscript.. 
17 
 
Figure legends 
Figure 1 
The serial change in glucose (A), triglyceride (TG) (B), remnant lipoprotein cholesterol (RLP-C) 
(C), apolipoprotein B-48 (ApoB-48) (D), glucagon-like peptide-1 (GLP-1) (E), and glucagon (F). 
*p<0.05 vs. control group. 
 
Figure 2 
The serial change in endothelial function after cookie ingestion in the alogliptin and control 
groups. FMD, flow-mediated dilation (A), and maximum decrease in the alogliptin and control 
groups (B). 
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Abbreviations 
 
apoB-48: apolipoprotein B48   
AUC: area under the curve   
BMI: body mass index   
DPP-4: dipeptidyl peptidase Ⅳ   
FMD: flow-mediated dilation   
GIP: glucose-dependent insulinotropic polypeptide   
GLP-1 :glucagon-like peptide-1   
HDL-C: high-density lipoprotein cholesterol   
HOMA-IR: homeostasis model assessment of insulin resistance 
LDL-C: low-density lipoprotein cholesterol  
NMD: nitroglycerin-mediated dilation   
RLP-C: remnant lipoprotein cholesterol   
SD: standard deviation   
SE: standard error   
TG: triglyceride   
Total-C: total cholesterol   
VCAM-1: vascular cell adhesion molecule 1   
 
25 
 
 Table 1. Characteristics of participants 
  Control (n = 10) Alogliptin (n = 10) p value 
Age (years） 35 ± 10 - - 
Male (%) 8 (80) - - 
Current Smoker (%) 3(30) - - 
HbA1c (%) 4.6 ± 0.3 - - 
BMI (kg/m2) 23.9 ± 4.1 23.9 ± 3.4 0.86 
Systolic blood pressure (mmHg) 122 ± 3 121 ± 3 0.35 
Diastolic blood pressure (mmHg) 71 ± 2 71 ± 2 0.99 
Heart rate (beats/min) 62 ± 3 61 ± 2 0.20 
Total-C (mg/dl) 185.3 ± 10.6 180.7 ± 9.9 0.58 
LDL-C (mg/dl) 103.2 ± 8.9 102.2 ± 9.3 0.72 
HDL-C (mg/dl) 66.3 ± 3.1 64.2 ± 3.4 0.29 
TG (mg/dl) 73.7 ± 10.2 63.4 ± 7.9 0.08 
RLP-C (mg/dl) 8.4 ± 1.2 6.7 ± 0.8 0.28 
ApoB-48 (μg/ml) 2.5 ± 0.3 2.2 ± 0.2 0.19 
Glucose (mg/dl) 93.0 ± 2.0 94.3 ± 2.1 0.54 
Glucagon (pg/ml) 63.5 ± 5.4 59.4 ± 2.8 0.44 
Insulin (μIU/ml) 4.8 ± 0.8 4.9 ± 1.3 0.38 
HOMA-IR 1.1 ± 0.2 1.1 ± 0.3 0.51 
GLP-1 (pmol/l) 3.2 ± 0.2 5.2 ± 0.7 0.03 
Adiponectin (μg/ml) 9.6 ± 0.8 9.7 ± 0.7 0.31 
Soluble VCAM-1 (ng/ml) 629 ± 72 606 ± 50 0.76 
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Data are the mean ± SE or frequency counts (percentages), as appropriate. BMI, body mass 
index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; 
TG, triglyceride; RLP-C, remnant lipoprotein cholesterol; ApoB-48, apolipoprotein B-48; 
HOMA-IR, homeostasis model assessment of insulin resistance; GLP-1, glucagon-like peptide-1; 
VCAM-1, vascular cell adhesion molecule-1.
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Table 2. Maximum change in lipids and glucose metabolism in the alogliptin and control groups. 
  Control Alogliptin p 
TG (mg/dl) 59.7 ± 7.8 48.3 ± 6.4 0.01 
RLP-C (mg/dl) 6.1 ± 0.6 4.8 ± 0.7 0.02 
ApoB-48 (μg/ml) 4.0 ± 0.4 2.8 ± 0.2 0.01 
Glucose (mg/dl) 20.5 ± 2.4 20.4 ±3.9  0.51 
Insulin (μIU/ml) 19.4 ± 6.3 18.2 ± 4.8 0.87 
GLP-1 (pmol/l) 5.4 ± 1.3 10.2 ± 1.3 0.04 
Data are the mean ± SE. TG, triglyceride; RLP-C, remnant lipoprotein cholesterol; ApoB-48, 
apolipoprotein B-48; GLP-1, glucagon-like peptide-1.  
 
